Beta Bionics Q2 Revenue Jumps 38%, Gross Margin Expands; Raises Full-Year Margin Outlook

summarizeSummary

Beta Bionics reported Q2 2026 revenue of $32 million (+38% YoY), raised full-year gross margin guidance, and highlighted pipeline progress including a pivotal type 2 diabetes trial. Cash of $225 million funds operations into 2028.

check_boxKey Events · Earnings and Guidance · BBNX

• Q2 Revenue Up 38% to $32M

  Net sales reached $32.0 million, driven by a 153% increase in the Pharmacy Benefit Plan channel to $11.6 million. DME channel sales grew 9% to $20.4 million.

• Gross Margin Expands to 59%

  Gross margin improved 524 basis points year-over-year to 59.0%, reflecting favorable product mix and operating leverage. Full-year gross margin guidance was raised to 58.5%-59.5%.

• Full-Year Revenue Guidance Maintained

  The company reiterated 2026 revenue guidance of $131-$136 million, implying ~120% growth at the midpoint, with no change to PBP channel mix expectations.

• Pipeline Advances: Type 2 Trial and Mint Pump

  Enrollment began for a pivotal U.S. trial of iLet in type 2 diabetes, with potential label expansion by mid-2027. Mint patch pump commercialization is targeted for end of Q2 2027, subject to FDA clearance.

auto_awesomeAnalysis · BBNX · Industrial Applications And Services

Beta Bionics delivered strong Q2 results with revenue up 38% to $32 million, driven by a 153% surge in pharmacy channel sales. Gross margin expanded 524 basis points to 59%, and the company raised its full-year gross margin guidance. Operating losses widened on higher commercial investment, but the $225 million cash position provides runway into 2028. The results come amid a securities investigation announced in June, making the strong operational performance a potential counterweight to legal overhang.